Evidence map›Paper›PMID 39175041›Full record

ArticlePhysiological reports2024

Aquaporin 1 confers apoptosis resistance in pulmonary arterial smooth muscle cells from the SU5416 hypoxia rat model.

Xin Yun, Shannon Niedermeyer, Manuella Ribas Andrade, Haiyang Jiang, Karthik Suresh, Todd Kolb, Mahendra Damarla, Larissa A Shimoda

Abstract read
In one paragraph

Article in Physiological reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. From development to regeneration: the endothelial interface in lung injury and repair.American journal of physiology. Lung cellular and molecular physiology · 2025
    Review
  3. [Application of Animal Models in Research on Hypoxia-Related Diseases].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xin YunDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Shannon NiedermeyerDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Manuella Ribas AndradeDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Haiyang JiangDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Karthik SureshDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Todd KolbDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Mahendra DamarlaDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Larissa A ShimodaDivision of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0001-5987-1378

Funding

MULTIDISCIPLINARY TRAINING PROGRAM IN LUNG DISEASEST32HL007534 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Nadia N Hansel, Larissa A. Shimoda · 1985 to 2026
$28.3M
Aquaporin 1 and pulmonary hypertensionR01HL126514 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SHIMODA, LARISSA A. · 2015 to 2025
$4.5M
Na+/H+ exchange in pulmonary hypertensionR01HL073859 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI SHIMODA, LARISSA A. · 2003 to 2020
$4.2M
MK2 and pulmonary hypertensionR01HL159906 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI DAMARLA, MAHENDRA, SHIMODA, LARISSA A. · 2021 to 2024
$3.0M
Mechanisms Driving Apoptosis Resistance in Pulmonary HypertensionF32HL165766 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI NIEDERMEYER, SHANNON · 2022 to 2024
$154k
American Heart Association (AHA) 18POST34030262American Heart Association (AHA) 23PRE1022720HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL126514NHLBI NIH HHS F32 HL165766NHLBI NIH HHS R01 HL073859NHLBI NIH HHS R01 HL126514NHLBI NIH HHS R01 HL159906NHLBI NIH HHS T32 HL007534
6 · The paper itself

Abstract

Pulmonary hypertension (PH) arises from increased pulmonary vascular resistance due to contraction and remodeling of the pulmonary arteries. The structural changes include thickening of the smooth muscle layer from increased proliferation and resistance to apoptosis. The mechanisms underlying apoptosis resistance in PH are not fully understood. In cancer cells, high expression of aquaporin 1 (AQP1), a water channel, is associated with apoptosis resistance. We showed AQP1 protein was expressed in pulmonary arterial smooth muscle cells (PASMCs) and upregulated in preclinical PH models. In this study, we used PASMCs isolated from control male rats and the SU5416 plus hypoxia (SuHx) model to test the role of AQP1 in modulating susceptibility to apoptosis. We found the elevated level of AQP1 in PASMCs from SuHx rats was necessary for resistance to apoptosis and that apoptosis resistance could be conferred by increasing AQP1 in control PASMCs. In exploring the downstream pathways involved, we found AQP1 levels influence the expression of Bcl-2, with enhanced AQP1 levels corresponding to increased Bcl-2 expression, reducing the ratio of BAX to Bcl-2, consistent with apoptosis resistance. These results provide a mechanism by which AQP1 can regulate PASMC fate.

Indexed as

ApoptosisAquaporin 1HypoxiaIndolesMuscle, Smooth, VascularMyocytes, Smooth MusclePulmonary ArteryPyrrolesAnimalsCells, CulturedDisease Models, AnimalHypertension, PulmonaryMaleProto-Oncogene Proteins c-bcl-2RatsRats, Sprague-DawleyAqp1 protein, ratAquaporin 1IndolesProto-Oncogene Proteins c-bcl-2PyrrolesSemaxinibcell deathlungpulmonary hypertensionremodeling

Identifiers

PMID39175041
PMCPMC11341275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.